SlideShare a Scribd company logo
PDPT Law in California and
 CFHC PDPT Guidelines
 Requirements for Participation in
CFHC’s PDPT Distribution Program


                    advocate facilitate evaluate educate research
CFHC’s PDPT Trainings

• This is Part 3 of a 3-part series on PDPT
   – Part 1: Background information about PDPT
   – Part 2: Using PDPT for Partner Management
   – Part 3: PDPT Law in California and
     CFHC PDPT Guidelines
• For more information on PDPT:
http://www.cdph.ca.gov/pubsforms/Guidelines/Documents/CA-STD-PDPT-Guideline




                                         advocate facilitate evaluate educate research
Background



             advocate facilitate evaluate educate research
CDC Supports PDPT!


“EPT should be available to clinicians as an
    option for partner management”


- Expedited Partner Therapy in the Management of Sexually Transmitted
 Diseases, http://www.cdc.gov/std/treatment/EPTFinalReport2006.pdf




                                        advocate facilitate evaluate educate research
CDC Recommendations:
   Does not replace other partner management
    strategies
   Used in situations in which the partner is not
    likely to receive treatment in a clinical setting.
   Along with medication, EPT should be
    accompanied by:
       Educational materials
       Information that advises recipients about how to
        seek personal health care in addition to EPT
                                  advocate facilitate evaluate educate research
Is PDPT for CT and GC Legal in
California?
                       YES!
2001 - State law in California allows clinicians to
provide treatment to partners of patients with
chlamydia

January 1, 2007 - law also allows PDPT for


gonorrhea

                              advocate facilitate evaluate educate research
Legal Status of EPT in the U.S.




*As of 02/2012

                    advocate facilitate evaluate educate research
CDC EPT Legal/Policy Toolkit




                         CDC EPT Legal/Policy Toolkit
                         http://www.cdc.gov/std/ept/
                         legal/legaltoolkit.htm



                  advocate facilitate evaluate educate research
California Guidelines

    Patient-Delivered Partner Therapy (PDPT) for
 Chlamydia trachomatis and Neisseria gonorrhoeae:
Interim* Guidance for Medical Providers in California
 Developed by: California Department of Public Health Sexually Transmitted
 Diseases (STD) Control Branch in collaboration with California STD Controllers
 Association, the California STD/HIV Prevention Training Center, and the
 California Chlamydia Action Coalition.
 *Published in 2011, based on 2007 PDPT Guidance and have been revised to include updated
 gonorrhea treatment recommendations for dual therapy and precautions relations to pharyngeal
 gonorrhea infections.
http://www.cdph.ca.gov/pubsforms/Guidelines/Documents/CA-STD-PDPT-Guidelines-1

                                     www.std.ca.gov
                                                         advocate facilitate evaluate educate research
CFHC PDPT Distribution
Program Requirements



                advocate facilitate evaluate educate research
CFHC PDPT Distribution Program:
Background
   Neither Medi-Cal nor Family PACT reimburse
    PDPT medication

   Therefore, CFHC provides FREE PDPT to Title X
    Delegate Agencies to increase access to
    partner treatment.


                             advocate facilitate evaluate educate research
CFHC PDPT Distribution Program
Requirements
1. Medication must be:
   Distributed free-of-charge to clients
   Prescribed solely to chlamydia- or gonorrhea-positive
    clients for treatment of their partners (i.e., use is
    restricted to patient-delivered partner therapy or
    take-home medication for partners)
   OR to uninsured clients eligible for Title X services,
    but not eligible for the Family PACT program.


                                  advocate facilitate evaluate educate research
CFHC PDPT Distribution Program
Requirements
2. Each dispensing clinic must maintain a
 medication log.
 The log must include:
       Date of visit
       Patient identifier (i.e. medical record
        number or name)
       Patient date of birth and gender.
                              advocate facilitate evaluate educate research
CFHC PDPT Distribution Program
Requirements




         Sample PDPT Log
                   advocate facilitate evaluate educate research
CFHC PDPT Distribution Program
Requirements
   A copy of each site’s log will be requested at
    the end of the 2nd and 4th quarters.
   These logs and a sample of patient charts may
    be reviewed during your agency’s next Title X
    site evaluation.




                              advocate facilitate evaluate educate research
CFHC PDPT Distribution Program
Requirements
 Samples of the chlamydia PDPT patient education
 handouts in English, Spanish, Chinese, and
 Vietnamese are available for free on the CFHC
 website, as well as gonorrhea PDPT patient
 education handouts in English and Spanish.



 http://www.cfhc.org/Resources/SamplesFile/sexuall
 y-transmitted-disease.html

                             advocate facilitate evaluate educate research
Questions?

 For CFHC PDPT Program information, please
                  contact:

         Aileen Barandas MSN, NP
          STD Programs Director
            barandasa@cfhc.org
          510.486.0412 ext 2334

                         advocate facilitate evaluate educate research
Medical and scientific consultation for this
 webcast was provided by the California
Department of Public Health, STD Control
                 Branch
   For more information, please visit
            www.std.ca.gov


                         advocate facilitate evaluate educate research

More Related Content

What's hot

Pharmacare - Caveat Emptor (Let the Buyer Beware)
Pharmacare - Caveat Emptor (Let the Buyer Beware)Pharmacare - Caveat Emptor (Let the Buyer Beware)
Pharmacare - Caveat Emptor (Let the Buyer Beware)
Canadian Cancer Survivor Network
 
Federal Election Special - What are the Parties Saying About Healthcare and C...
Federal Election Special - What are the Parties Saying About Healthcare and C...Federal Election Special - What are the Parties Saying About Healthcare and C...
Federal Election Special - What are the Parties Saying About Healthcare and C...
Canadian Cancer Survivor Network
 
Canada Market Access Briefing
Canada Market Access BriefingCanada Market Access Briefing
Canada Market Access BriefingMichael Jacobson
 
The Mad, Fairytale World of Drug Approval in Canada
The Mad, Fairytale World of Drug Approval in CanadaThe Mad, Fairytale World of Drug Approval in Canada
The Mad, Fairytale World of Drug Approval in Canada
Canadian Cancer Survivor Network
 
The involvement of patients and survivors in volunteer advocacy survey
The involvement of patients and survivors in volunteer advocacy surveyThe involvement of patients and survivors in volunteer advocacy survey
The involvement of patients and survivors in volunteer advocacy survey
Canadian Cancer Survivor Network
 
What chronic disease advocacy can offer cancer survivors - round table discus...
What chronic disease advocacy can offer cancer survivors - round table discus...What chronic disease advocacy can offer cancer survivors - round table discus...
What chronic disease advocacy can offer cancer survivors - round table discus...
Canadian Cancer Survivor Network
 
VFCC_-_A_Medical_Cannabis_Clinical_Model___Nov_2014_(rs)-5 copy
VFCC_-_A_Medical_Cannabis_Clinical_Model___Nov_2014_(rs)-5 copyVFCC_-_A_Medical_Cannabis_Clinical_Model___Nov_2014_(rs)-5 copy
VFCC_-_A_Medical_Cannabis_Clinical_Model___Nov_2014_(rs)-5 copyMatthew Boyle
 
Who expert committee recommendations for pharmaceutical products
Who expert committee recommendations for pharmaceutical productsWho expert committee recommendations for pharmaceutical products
Who expert committee recommendations for pharmaceutical productsswati2084
 
Case study cdr p cpa re kuvan for cord november 2015
Case study cdr p cpa re kuvan for cord november 2015Case study cdr p cpa re kuvan for cord november 2015
Case study cdr p cpa re kuvan for cord november 2015
Canadian Organization for Rare Disorders
 
Evidence-Based Approach to Assuring Value for Orphan Drugs: Pam Gavin (NORD)
Evidence-Based Approach to Assuring Value for Orphan Drugs: Pam Gavin (NORD)Evidence-Based Approach to Assuring Value for Orphan Drugs: Pam Gavin (NORD)
Evidence-Based Approach to Assuring Value for Orphan Drugs: Pam Gavin (NORD)
Canadian Organization for Rare Disorders
 
Meaningful use (mu) 101
Meaningful use (mu) 101Meaningful use (mu) 101
Meaningful use (mu) 101
Rex Osborn
 
Funding of Drugs for Rare Diseases Provincial Program Perspective
Funding of Drugs for Rare Diseases Provincial Program PerspectiveFunding of Drugs for Rare Diseases Provincial Program Perspective
Funding of Drugs for Rare Diseases Provincial Program Perspective
Canadian Organization for Rare Disorders
 
New Directions in Drug Approval in Canada
New Directions in Drug Approval in CanadaNew Directions in Drug Approval in Canada
New Directions in Drug Approval in Canada
Canadian Cancer Survivor Network
 
Market Access Climate Change Webinar_the Evolving Impact of Product Listing A...
Market Access Climate Change Webinar_the Evolving Impact of Product Listing A...Market Access Climate Change Webinar_the Evolving Impact of Product Listing A...
Market Access Climate Change Webinar_the Evolving Impact of Product Listing A...Arvind Mani
 
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canadian Organization for Rare Disorders
 
The importance of clinician engagement in the HTA process
The importance of clinician engagement in the HTA processThe importance of clinician engagement in the HTA process
The importance of clinician engagement in the HTA process
Canadian Cancer Survivor Network
 
Rare Cancers - How to Empower Patients & Advocacy Organizations through Colla...
Rare Cancers - How to Empower Patients & Advocacy Organizations through Colla...Rare Cancers - How to Empower Patients & Advocacy Organizations through Colla...
Rare Cancers - How to Empower Patients & Advocacy Organizations through Colla...
Canadian Cancer Survivor Network
 
Speakers' bios
Speakers' biosSpeakers' bios
Drug Approval & Reimbursement Processes
Drug Approval & Reimbursement ProcessesDrug Approval & Reimbursement Processes
Drug Approval & Reimbursement Processes
Canadian Cancer Survivor Network
 
Special Access and Advanced Access Programmes: Marion Law (Health Canada)
Special Access and Advanced Access Programmes: Marion Law (Health Canada)Special Access and Advanced Access Programmes: Marion Law (Health Canada)
Special Access and Advanced Access Programmes: Marion Law (Health Canada)
Canadian Organization for Rare Disorders
 

What's hot (20)

Pharmacare - Caveat Emptor (Let the Buyer Beware)
Pharmacare - Caveat Emptor (Let the Buyer Beware)Pharmacare - Caveat Emptor (Let the Buyer Beware)
Pharmacare - Caveat Emptor (Let the Buyer Beware)
 
Federal Election Special - What are the Parties Saying About Healthcare and C...
Federal Election Special - What are the Parties Saying About Healthcare and C...Federal Election Special - What are the Parties Saying About Healthcare and C...
Federal Election Special - What are the Parties Saying About Healthcare and C...
 
Canada Market Access Briefing
Canada Market Access BriefingCanada Market Access Briefing
Canada Market Access Briefing
 
The Mad, Fairytale World of Drug Approval in Canada
The Mad, Fairytale World of Drug Approval in CanadaThe Mad, Fairytale World of Drug Approval in Canada
The Mad, Fairytale World of Drug Approval in Canada
 
The involvement of patients and survivors in volunteer advocacy survey
The involvement of patients and survivors in volunteer advocacy surveyThe involvement of patients and survivors in volunteer advocacy survey
The involvement of patients and survivors in volunteer advocacy survey
 
What chronic disease advocacy can offer cancer survivors - round table discus...
What chronic disease advocacy can offer cancer survivors - round table discus...What chronic disease advocacy can offer cancer survivors - round table discus...
What chronic disease advocacy can offer cancer survivors - round table discus...
 
VFCC_-_A_Medical_Cannabis_Clinical_Model___Nov_2014_(rs)-5 copy
VFCC_-_A_Medical_Cannabis_Clinical_Model___Nov_2014_(rs)-5 copyVFCC_-_A_Medical_Cannabis_Clinical_Model___Nov_2014_(rs)-5 copy
VFCC_-_A_Medical_Cannabis_Clinical_Model___Nov_2014_(rs)-5 copy
 
Who expert committee recommendations for pharmaceutical products
Who expert committee recommendations for pharmaceutical productsWho expert committee recommendations for pharmaceutical products
Who expert committee recommendations for pharmaceutical products
 
Case study cdr p cpa re kuvan for cord november 2015
Case study cdr p cpa re kuvan for cord november 2015Case study cdr p cpa re kuvan for cord november 2015
Case study cdr p cpa re kuvan for cord november 2015
 
Evidence-Based Approach to Assuring Value for Orphan Drugs: Pam Gavin (NORD)
Evidence-Based Approach to Assuring Value for Orphan Drugs: Pam Gavin (NORD)Evidence-Based Approach to Assuring Value for Orphan Drugs: Pam Gavin (NORD)
Evidence-Based Approach to Assuring Value for Orphan Drugs: Pam Gavin (NORD)
 
Meaningful use (mu) 101
Meaningful use (mu) 101Meaningful use (mu) 101
Meaningful use (mu) 101
 
Funding of Drugs for Rare Diseases Provincial Program Perspective
Funding of Drugs for Rare Diseases Provincial Program PerspectiveFunding of Drugs for Rare Diseases Provincial Program Perspective
Funding of Drugs for Rare Diseases Provincial Program Perspective
 
New Directions in Drug Approval in Canada
New Directions in Drug Approval in CanadaNew Directions in Drug Approval in Canada
New Directions in Drug Approval in Canada
 
Market Access Climate Change Webinar_the Evolving Impact of Product Listing A...
Market Access Climate Change Webinar_the Evolving Impact of Product Listing A...Market Access Climate Change Webinar_the Evolving Impact of Product Listing A...
Market Access Climate Change Webinar_the Evolving Impact of Product Listing A...
 
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
 
The importance of clinician engagement in the HTA process
The importance of clinician engagement in the HTA processThe importance of clinician engagement in the HTA process
The importance of clinician engagement in the HTA process
 
Rare Cancers - How to Empower Patients & Advocacy Organizations through Colla...
Rare Cancers - How to Empower Patients & Advocacy Organizations through Colla...Rare Cancers - How to Empower Patients & Advocacy Organizations through Colla...
Rare Cancers - How to Empower Patients & Advocacy Organizations through Colla...
 
Speakers' bios
Speakers' biosSpeakers' bios
Speakers' bios
 
Drug Approval & Reimbursement Processes
Drug Approval & Reimbursement ProcessesDrug Approval & Reimbursement Processes
Drug Approval & Reimbursement Processes
 
Special Access and Advanced Access Programmes: Marion Law (Health Canada)
Special Access and Advanced Access Programmes: Marion Law (Health Canada)Special Access and Advanced Access Programmes: Marion Law (Health Canada)
Special Access and Advanced Access Programmes: Marion Law (Health Canada)
 

Similar to PDPT Webcast - Part 3 - The Law and CFHC Requirements

Incorporating Patient Preferences Into the HTA Deliberative Framework: The Pa...
Incorporating Patient Preferences Into the HTA Deliberative Framework: The Pa...Incorporating Patient Preferences Into the HTA Deliberative Framework: The Pa...
Incorporating Patient Preferences Into the HTA Deliberative Framework: The Pa...
Canadian Organization for Rare Disorders
 
Drug information centre resources@clinical pharmacy 4th pharm D
Drug information centre resources@clinical pharmacy 4th pharm DDrug information centre resources@clinical pharmacy 4th pharm D
Drug information centre resources@clinical pharmacy 4th pharm D
Drpradeepthi
 
dic resources.pptx in pharmacoepidemiology
dic resources.pptx in pharmacoepidemiologydic resources.pptx in pharmacoepidemiology
dic resources.pptx in pharmacoepidemiology
Drpradeepthi
 
Who Wants To Be A Vaccinator
Who Wants To Be A Vaccinator Who Wants To Be A Vaccinator
Who Wants To Be A Vaccinator
CHC Connecticut
 
Patient Engagement in Drug Review: Helen Mai (CADTH)
Patient Engagement in Drug Review: Helen Mai (CADTH)Patient Engagement in Drug Review: Helen Mai (CADTH)
Patient Engagement in Drug Review: Helen Mai (CADTH)
Canadian Organization for Rare Disorders
 
Hepatitis C Drugs - Evidence to Demonstrate Effectiveness & Value
Hepatitis C Drugs - Evidence to Demonstrate Effectiveness & ValueHepatitis C Drugs - Evidence to Demonstrate Effectiveness & Value
Hepatitis C Drugs - Evidence to Demonstrate Effectiveness & Value
Center for Medical Technology Policy
 
Clinical Pharmacology: Leveraging Science to Provide Access
Clinical Pharmacology: Leveraging Science to Provide AccessClinical Pharmacology: Leveraging Science to Provide Access
Clinical Pharmacology: Leveraging Science to Provide Access
E. Dennis Bashaw
 
Contracts and Memorandums of Understanding - Requirements and Responsibilities
Contracts and Memorandums of Understanding - Requirements and ResponsibilitiesContracts and Memorandums of Understanding - Requirements and Responsibilities
Contracts and Memorandums of Understanding - Requirements and Responsibilities
Compliatric Where Compliance Happens
 
2023 Compliatric Webinar Series - Contracts and Memorandums of Understanding ...
2023 Compliatric Webinar Series - Contracts and Memorandums of Understanding ...2023 Compliatric Webinar Series - Contracts and Memorandums of Understanding ...
2023 Compliatric Webinar Series - Contracts and Memorandums of Understanding ...
Compliatric Where Compliance Happens
 
CMT update 2014 fall
CMT update 2014 fallCMT update 2014 fall
CMT update 2014 fall
Sean Ekins
 
Hcv guidance april-2017
Hcv guidance april-2017Hcv guidance april-2017
Hcv guidance april-2017
Prof. Ahmed Mohamed Badheeb
 
Accessing Diabetes Education Through Telehealth
Accessing Diabetes Education Through TelehealthAccessing Diabetes Education Through Telehealth
Accessing Diabetes Education Through Telehealth
TAOklahoma
 
PDPT Webcast - Part 1 - Patient Deliver Partner Therapy 101
PDPT Webcast - Part 1 - Patient Deliver Partner Therapy 101PDPT Webcast - Part 1 - Patient Deliver Partner Therapy 101
PDPT Webcast - Part 1 - Patient Deliver Partner Therapy 101
California Family Health Council
 
Drug information and poison information
Drug information and poison informationDrug information and poison information
Drug information and poison information
THUSHARA MOHAN
 
Drug information center (dic)
Drug information center (dic)Drug information center (dic)
Drug information center (dic)
Snehal Wani Chaudhari
 
Abpi launched clinical trial disclosure toolkit
Abpi launched clinical trial disclosure toolkitAbpi launched clinical trial disclosure toolkit
Abpi launched clinical trial disclosure toolkit
sushant deshmukh
 
Abpi launched clinical-trial_disclosure_toolkit
Abpi launched clinical-trial_disclosure_toolkitAbpi launched clinical-trial_disclosure_toolkit
Abpi launched clinical-trial_disclosure_toolkit
sushant deshmukh
 
CCSN Webinar Patient Input into HTA Decision Making Oct 5 2023.pptx
CCSN Webinar Patient Input into HTA Decision Making Oct 5 2023.pptxCCSN Webinar Patient Input into HTA Decision Making Oct 5 2023.pptx
CCSN Webinar Patient Input into HTA Decision Making Oct 5 2023.pptx
Canadian Cancer Survivor Network
 
How to Avoid Being a Target in the Mental Health Outpatient World
How to Avoid Being a Target in the Mental Health Outpatient WorldHow to Avoid Being a Target in the Mental Health Outpatient World
How to Avoid Being a Target in the Mental Health Outpatient World
PYA, P.C.
 

Similar to PDPT Webcast - Part 3 - The Law and CFHC Requirements (20)

Incorporating Patient Preferences Into the HTA Deliberative Framework: The Pa...
Incorporating Patient Preferences Into the HTA Deliberative Framework: The Pa...Incorporating Patient Preferences Into the HTA Deliberative Framework: The Pa...
Incorporating Patient Preferences Into the HTA Deliberative Framework: The Pa...
 
Drug information centre resources@clinical pharmacy 4th pharm D
Drug information centre resources@clinical pharmacy 4th pharm DDrug information centre resources@clinical pharmacy 4th pharm D
Drug information centre resources@clinical pharmacy 4th pharm D
 
dic resources.pptx in pharmacoepidemiology
dic resources.pptx in pharmacoepidemiologydic resources.pptx in pharmacoepidemiology
dic resources.pptx in pharmacoepidemiology
 
Who Wants To Be A Vaccinator
Who Wants To Be A Vaccinator Who Wants To Be A Vaccinator
Who Wants To Be A Vaccinator
 
Mini Grant Second Quarterly Call
Mini Grant Second Quarterly Call Mini Grant Second Quarterly Call
Mini Grant Second Quarterly Call
 
Patient Engagement in Drug Review: Helen Mai (CADTH)
Patient Engagement in Drug Review: Helen Mai (CADTH)Patient Engagement in Drug Review: Helen Mai (CADTH)
Patient Engagement in Drug Review: Helen Mai (CADTH)
 
Hepatitis C Drugs - Evidence to Demonstrate Effectiveness & Value
Hepatitis C Drugs - Evidence to Demonstrate Effectiveness & ValueHepatitis C Drugs - Evidence to Demonstrate Effectiveness & Value
Hepatitis C Drugs - Evidence to Demonstrate Effectiveness & Value
 
Clinical Pharmacology: Leveraging Science to Provide Access
Clinical Pharmacology: Leveraging Science to Provide AccessClinical Pharmacology: Leveraging Science to Provide Access
Clinical Pharmacology: Leveraging Science to Provide Access
 
Contracts and Memorandums of Understanding - Requirements and Responsibilities
Contracts and Memorandums of Understanding - Requirements and ResponsibilitiesContracts and Memorandums of Understanding - Requirements and Responsibilities
Contracts and Memorandums of Understanding - Requirements and Responsibilities
 
2023 Compliatric Webinar Series - Contracts and Memorandums of Understanding ...
2023 Compliatric Webinar Series - Contracts and Memorandums of Understanding ...2023 Compliatric Webinar Series - Contracts and Memorandums of Understanding ...
2023 Compliatric Webinar Series - Contracts and Memorandums of Understanding ...
 
CMT update 2014 fall
CMT update 2014 fallCMT update 2014 fall
CMT update 2014 fall
 
Hcv guidance april-2017
Hcv guidance april-2017Hcv guidance april-2017
Hcv guidance april-2017
 
Accessing Diabetes Education Through Telehealth
Accessing Diabetes Education Through TelehealthAccessing Diabetes Education Through Telehealth
Accessing Diabetes Education Through Telehealth
 
PDPT Webcast - Part 1 - Patient Deliver Partner Therapy 101
PDPT Webcast - Part 1 - Patient Deliver Partner Therapy 101PDPT Webcast - Part 1 - Patient Deliver Partner Therapy 101
PDPT Webcast - Part 1 - Patient Deliver Partner Therapy 101
 
Drug information and poison information
Drug information and poison informationDrug information and poison information
Drug information and poison information
 
Drug information center (dic)
Drug information center (dic)Drug information center (dic)
Drug information center (dic)
 
Abpi launched clinical trial disclosure toolkit
Abpi launched clinical trial disclosure toolkitAbpi launched clinical trial disclosure toolkit
Abpi launched clinical trial disclosure toolkit
 
Abpi launched clinical-trial_disclosure_toolkit
Abpi launched clinical-trial_disclosure_toolkitAbpi launched clinical-trial_disclosure_toolkit
Abpi launched clinical-trial_disclosure_toolkit
 
CCSN Webinar Patient Input into HTA Decision Making Oct 5 2023.pptx
CCSN Webinar Patient Input into HTA Decision Making Oct 5 2023.pptxCCSN Webinar Patient Input into HTA Decision Making Oct 5 2023.pptx
CCSN Webinar Patient Input into HTA Decision Making Oct 5 2023.pptx
 
How to Avoid Being a Target in the Mental Health Outpatient World
How to Avoid Being a Target in the Mental Health Outpatient WorldHow to Avoid Being a Target in the Mental Health Outpatient World
How to Avoid Being a Target in the Mental Health Outpatient World
 

Recently uploaded

Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
NephroTube - Dr.Gawad
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
KafrELShiekh University
 
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradeshBasavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Dr. Madduru Muni Haritha
 
263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,
sisternakatoto
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
Jim Jacob Roy
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
GL Anaacs
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
planning for change nursing Management ppt
planning for change nursing Management pptplanning for change nursing Management ppt
planning for change nursing Management ppt
Thangamjayarani
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
Little Cross Family Clinic
 
Sex determination from mandible pelvis and skull
Sex determination from mandible pelvis and skullSex determination from mandible pelvis and skull
Sex determination from mandible pelvis and skull
ShashankRoodkee
 
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in DehradunDehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
chandankumarsmartiso
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
Swetaba Besh
 
Light House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat EuropeLight House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat Europe
Lighthouse Retreat
 
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptxThyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
Dr. Vinay Pareek
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
Anurag Sharma
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
MedicoseAcademics
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
pal078100
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
greendigital
 

Recently uploaded (20)

Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
 
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradeshBasavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
 
263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
 
planning for change nursing Management ppt
planning for change nursing Management pptplanning for change nursing Management ppt
planning for change nursing Management ppt
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
 
Sex determination from mandible pelvis and skull
Sex determination from mandible pelvis and skullSex determination from mandible pelvis and skull
Sex determination from mandible pelvis and skull
 
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in DehradunDehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
 
Light House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat EuropeLight House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat Europe
 
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptxThyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
 

PDPT Webcast - Part 3 - The Law and CFHC Requirements

  • 1. PDPT Law in California and CFHC PDPT Guidelines Requirements for Participation in CFHC’s PDPT Distribution Program advocate facilitate evaluate educate research
  • 2. CFHC’s PDPT Trainings • This is Part 3 of a 3-part series on PDPT – Part 1: Background information about PDPT – Part 2: Using PDPT for Partner Management – Part 3: PDPT Law in California and CFHC PDPT Guidelines • For more information on PDPT: http://www.cdph.ca.gov/pubsforms/Guidelines/Documents/CA-STD-PDPT-Guideline advocate facilitate evaluate educate research
  • 3. Background advocate facilitate evaluate educate research
  • 4. CDC Supports PDPT! “EPT should be available to clinicians as an option for partner management” - Expedited Partner Therapy in the Management of Sexually Transmitted Diseases, http://www.cdc.gov/std/treatment/EPTFinalReport2006.pdf advocate facilitate evaluate educate research
  • 5. CDC Recommendations:  Does not replace other partner management strategies  Used in situations in which the partner is not likely to receive treatment in a clinical setting.  Along with medication, EPT should be accompanied by:  Educational materials  Information that advises recipients about how to seek personal health care in addition to EPT advocate facilitate evaluate educate research
  • 6. Is PDPT for CT and GC Legal in California? YES! 2001 - State law in California allows clinicians to provide treatment to partners of patients with chlamydia January 1, 2007 - law also allows PDPT for  gonorrhea advocate facilitate evaluate educate research
  • 7. Legal Status of EPT in the U.S. *As of 02/2012 advocate facilitate evaluate educate research
  • 8. CDC EPT Legal/Policy Toolkit CDC EPT Legal/Policy Toolkit http://www.cdc.gov/std/ept/ legal/legaltoolkit.htm advocate facilitate evaluate educate research
  • 9. California Guidelines Patient-Delivered Partner Therapy (PDPT) for Chlamydia trachomatis and Neisseria gonorrhoeae: Interim* Guidance for Medical Providers in California Developed by: California Department of Public Health Sexually Transmitted Diseases (STD) Control Branch in collaboration with California STD Controllers Association, the California STD/HIV Prevention Training Center, and the California Chlamydia Action Coalition. *Published in 2011, based on 2007 PDPT Guidance and have been revised to include updated gonorrhea treatment recommendations for dual therapy and precautions relations to pharyngeal gonorrhea infections. http://www.cdph.ca.gov/pubsforms/Guidelines/Documents/CA-STD-PDPT-Guidelines-1 www.std.ca.gov advocate facilitate evaluate educate research
  • 10. CFHC PDPT Distribution Program Requirements advocate facilitate evaluate educate research
  • 11. CFHC PDPT Distribution Program: Background  Neither Medi-Cal nor Family PACT reimburse PDPT medication  Therefore, CFHC provides FREE PDPT to Title X Delegate Agencies to increase access to partner treatment. advocate facilitate evaluate educate research
  • 12. CFHC PDPT Distribution Program Requirements 1. Medication must be:  Distributed free-of-charge to clients  Prescribed solely to chlamydia- or gonorrhea-positive clients for treatment of their partners (i.e., use is restricted to patient-delivered partner therapy or take-home medication for partners)  OR to uninsured clients eligible for Title X services, but not eligible for the Family PACT program. advocate facilitate evaluate educate research
  • 13. CFHC PDPT Distribution Program Requirements 2. Each dispensing clinic must maintain a medication log. The log must include:  Date of visit  Patient identifier (i.e. medical record number or name)  Patient date of birth and gender. advocate facilitate evaluate educate research
  • 14. CFHC PDPT Distribution Program Requirements Sample PDPT Log advocate facilitate evaluate educate research
  • 15. CFHC PDPT Distribution Program Requirements  A copy of each site’s log will be requested at the end of the 2nd and 4th quarters.  These logs and a sample of patient charts may be reviewed during your agency’s next Title X site evaluation. advocate facilitate evaluate educate research
  • 16. CFHC PDPT Distribution Program Requirements Samples of the chlamydia PDPT patient education handouts in English, Spanish, Chinese, and Vietnamese are available for free on the CFHC website, as well as gonorrhea PDPT patient education handouts in English and Spanish. http://www.cfhc.org/Resources/SamplesFile/sexuall y-transmitted-disease.html advocate facilitate evaluate educate research
  • 17. Questions? For CFHC PDPT Program information, please contact: Aileen Barandas MSN, NP STD Programs Director barandasa@cfhc.org 510.486.0412 ext 2334 advocate facilitate evaluate educate research
  • 18. Medical and scientific consultation for this webcast was provided by the California Department of Public Health, STD Control Branch For more information, please visit www.std.ca.gov advocate facilitate evaluate educate research

Editor's Notes

  1. Hello, and welcome to the California Family Health Council’s webcasts about Patient Delivered Partner Therapy, or PDPT. I’m Linda Creegan, family nurse practitioner with the California STD/HIV Prevention Training Center.
  2. This webcast is Part 3 of a 3-part series about partner delivered partner therapy. In this segment, I’ll be discussing California law as it relates to PDPT, and the California Family Health Council’s Azithromycin distribution program for PDPT. Please listen to Parts 1 and 2 for more information about the important background information about chlamydia and gonorrhea infections, and about the specifics of using PDPT in your clinic settings.
  3. First, a bit of background regarding
  4. In 2006, the CDC released a document called Expedited Partner Therapy in Sexually Transmitted Diseases, which includes guidance about using patient delivered partner therapy. CDC clearly supports the use of PDPT, by stating that expedited partner therapy should be available to clinicians as an option for partner management.
  5. As discussed in the previous webcasts, PDPT should not be regarded as a first line approach to partner management. Really it is reserved for use with those partners who the patient believes will not get treatment unless they are brought the medication. And the medication used for PDPT should always come with thorough written education materials that explain about the infection, about the medication, and about where to find medical care.
  6. California also supports the use of PDPT. Since 2001 for chlamydia, and since 2007 for gonorrhea, laws are in place that expressly allow clinicians to provide treatment to partners.
  7. You may be interested in consulting the CDC’s webpages about PDPT. You’ll find a map of the U.S. that is constantly updated, as more states pass laws or regulations supporting PDPT, similar to those in California.
  8. And you’ll find this tool kit about legal and policy issues.
  9. For thorough guidance specific to the use of PDPT in California, visit the website of the STD Control Branch of the California Department of Public Health. Here you will find the most up-to-date information about the background to PDPT recommendations, and about implementing PDPT in your clinic.
  10. Finally, let’s spend a few minutes to talk about a great program sponsored by the California Family Health Council, which supplies azithromycin to Title X clinics free of charge for use as PDPT.
  11. Paying for the partner’s medication is often a barrier to treatment. Neither Medi-Cal nor Family PACT pays for PDPT. So several years ago, CFHC started an axithromycin distribution program, providing azithromycin to clinics like yours, specifially for use as PDPT.
  12. Here are the requirement for use of this medications.
  13. This is an example of the type of log you would keep.
  14. During you site evaluations, these logs will be reviewed to asure compliance with the requirements of this program.
  15. The California Family Health Council has examples of PDPT information factsheets in several languages, which you can use with PDPT. Here’s that web address…..
  16. Your contact for more information about the azithromycin distribution program and any questions you may have is Aileen Barandas at CFHC; here is her email address and phone number. If you haven’t already, be sure to listen to the other 2 short webcasts, about the background reasons for PDPT, and about implementing the use of PDPT in your clinic setting. Thanks for listening to these webcasts, and thanks for the work you do.